Mail Stop Interference P.O. Box 1450 Alexandria Va 22313-1450

Tel: 571-272-9797 Fax: 571-273-0042 Filed November 23, 2009

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

UCB Pharma S.A.
Junior Party
(Application 10/938,117,
Inventors: John Robert Adair, Diljeet Singh Athwal and
John Spencer Emtage),

v.

PDL Biopharma, Inc., Senior Party (Patent 6,180,370,

Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh and Harold E. Selick).

Patent Interference No. 105,705 (RES) (Technology Center 1600)

DECLARATION - 37 CFR § 41.203(b)

Part A. Declaration of interference

- 1 An interference is declared (35 U.S.C. § 135(a)) between the above-
- 2 identified parties. Details of the application(s), patent (if any), reissue application
- 3 (if any), count(s) and claims designated as corresponding or as not corresponding
- 4 to the count(s) appear in Parts E and F of this DECLARATION.

1	Part B. Judge managing the interference		
2	Administrative Patent Judge Richard Schafer has been designated to manage		
3	the interference. 37 CFR § 41.104(a).		
4	Part C. Standing order		
5	A Trial Section STANDING ORDER [SO] (Paper 2) accompanies this		
6	DECLARATION. The STANDING ORDER applies to this interference.		
7	Part D. Initial conference call		
8	A telephone conference call to discuss the interference is set for 4:00 p.m.		
9	on January 19, 2010 (the Board will initiate the call).		
10	No later than four business days prior to the conference call, each party		
11	shall file and serve (SO ¶¶ 10.1 & 105) a list of the motions (37 CFR § 41.120; 37		
12	CFR § 41.204; SO ¶¶ 104.2.1, 120 & 204) the party desires to file.		
13	The time periods for taking action during the motion phase are set in an		
14	order accompanying this declaration.		
15	Part E. Identification and order of the parties		
16		Junior Party	
17 18 19	Named inventors:	John Robert Adair Diljeet Singh Athwal John Spencer Emtage	
20	Involved Application:	10/938,117	
21	Title:	Humanized Antibodies	
22 23 24	Assignee of record:	UCB Pharma S.A. 60 Allee De La Recherche Brussels, Belgium B-1070	

1	Senior Party		
2 3 4 5 6 7	Named Inventors:	Cary L. Queen Man Sung Co William P. Schneider Nicholas F. Landolfi Kathleen L. Coelingh Harold E. Selick	
8	Involved Patent:	6,180,370	
9 10	Title:	Humanized Imminoglobulins and Methods of Making the same	
11	Assignee:	PDL Biopharma, Inc.	
12		34801 Campus Drive	
13		Fremont, California 94555	
14	The senior party is assigned exhibit numbers 1001-1999. The junior party is		
15	assigned exhibit numbers 2001-2999. 37 CFR § 41.154(c)(1); SO & 154.2.1. The		
16	senior party is responsible for initiating settlement discussions. SO & 126.1.		
17	Part F. Count and claims of the parties		
18	Count 1		
19 20 21 22 23 24 25 26 27 28 29 30	A substantially non-immunogenic humanized immunoglobulin useful in treating human disorders susceptible to monoclonal antibody therapy having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chain frameworks, which humanized immunoglobulin specifically binds to an antigen with a binding affinity of at least $10^8 \mathrm{M}^{-1}$ wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside the hypervariable regions or outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids — replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids is adjacent a CDR in the donor immunoglobulin sequence or is capable of		

1 2 3 4 5 6 7	interacting with the CDRs, or is typical as its position for human immunoglobulin sequences wherein said humanized immunoglobulin is a complete antibody molecule, having full length heavy and light chains; a fragment thereof; a light chain or heavy chain monomer or dimer; an antibody tetramer, or a single chain antibody. The claims of the parties are:			
8	Patent 6,180,370:	Claims 1-30		
9	Application: 10/938,117:	Claims: 24, 26, 27 and 29		
10	The claims of the parties which correspond to Count 1 are:			
11	Patent 6,180,370:	Claims 9-24, 28-30		
12	Application: 10/938,117:	Claims: 24, 26, 27 and 29		
13	The claims of the parties which do not correspond to Count 1, and therefore			
14	are not involved in the interference, are:			
15	Patent 6,180,370:	Claims 1-8, 25-27		
16	Application: 10/938,117:	Claims None		
17	The parties are accorded the following	ng benefit for Count 1:		
18	Patent 6,180,370:	None		
19	Application: 10/938,117:	None		

- 1 Part G. Heading to be used on papers
- 2 The following heading must be used on all papers filed in this interference,
- 3 see SO ¶ 106.1.1:

Filed on behalf of: *Party* @.

By: *Counsel Name(s)* @ *Address* @

(@@@) @@@- @@@@ (telephone)

(@@@) @@@- @@@@ (facsimile)

Paper No: Leave blank

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES

UCB Pharma S.A.

Junior Party

(Application 10/938,117,

Inventors: John Robert Adair, Diljeet Singh Athwal and
John Spencer Emtage),

V.

PDL Biopharma, Inc., Senior Party (Patent 6,180,370,

Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh and Harold E. Selick).

Patent Interference No. 105,705 (RES) (Technology Center 1600)

Title of Paper

1	
2	Part H. Order form for requesting file copies
3	When requesting copies of files, use of SO Form 4 will greatly expedite
4	processing of the request. Please attach a copy of Parts E and F of this
5	DECLARATION with a hand-drawn circle around the patents and applications for
6	which a copy of a file wrapper is requested.

/Richard E. Schafer/ Administrative Patent Judge

Enc:

Copy of STANDING ORDER Copy of claims of Application 10/938,117

cc (via overnight delivery):

Attorney for PDL Biopharma, Inc.:

Townsend and Townsend and Crew, LLP Two Embarcadero Center Eighth Floor San Francisco CA 94111-3834

Attorney for UCB Pharma S.A.:

Cozen O'Connor, P.C. 1900 Market Street Philadelphia PA 19103-3508